Last reviewed · How we verify
Tobramycin inhalation powder
At a glance
| Generic name | Tobramycin inhalation powder |
|---|---|
| Also known as | Bramitob, TIP, TIS, Antimicrobial non-nebulized inhalation preparations, TOBI® |
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution
- Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
- Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules (PHASE4)
- DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis (PHASE1, PHASE2)
- Second Open Label Extension to Bridging Study CTBM100C2303 (PHASE3)
- Open Label Extension to Bridging Study CTBM100C2303 (PHASE3)
- Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex (PHASE1)
- Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tobramycin inhalation powder CI brief — competitive landscape report
- Tobramycin inhalation powder updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI